AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-19. (cancelled)

- 20.(new) An isolated peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 2 or SEQ ID NO: 3, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to glycoaminoglycans (GAG).
- 21.(new) The isolated peptide of claim 20, wherein the amino sequence of said peptide differs from SEQ ID NO: 2 or SEQ ID NO: 3 by a conservative substitution of at least one amino acid.
- 22. (new) The isolated peptide of claim 20, wherein the amino acid sequence of said peptide consists of SEQ ID NO: 2 or SEQ ID NO: 3.
- 23. (new) An isolated nucleic acid comprising a sequence that encodes the isolated peptide of claim 20.
- 24. (new) The isolated nucleic acid of claim 23, wherein the sequence of said nucleic acid comprises the nucleotide sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

Docket No. 0512-1277 Appln. No. 10/533,443

- 25. (new) A method of producing the isolated peptide of claim 20, said method comprising synthesizing said peptide by chemical means.
- 26. (new) A method of producing the isolated peptide of claim 20, said method comprising culturing a host cell transformed with a vector containing a nucleic acid that encodes said isolated peptide, under conditions permitting the expression of the peptide.
- 27. (new) A pharmaceutical composition comprising the isolated peptide of claim 20, and at least one pharmaceutically acceptable excipient.
- 28. (new) The pharmaceutical composition of claim 27, further comprising a peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.
- 29. (new) The pharmaceutical composition of claim 28, wherein the amino acid sequence of said further peptide consists of SEQ ID NO: 4.

- 30. (new) The pharmaceutical composition of claim 28, comprising:
- (a) the peptide consisting of the amino acid sequence of SEQ $\,$ ID NO: 2;
- (b) the peptide consisting of the amino acid sequence of SEQ ID NO: 3; and
- (c) the peptide consisting of the amino acid sequence of SEQ $\scriptstyle\rm ID$ NO: 4.
- 31. (new) A pharmaceutical composition comprising a nucleic acid that comprises a sequence that encodes the isolated peptide of claim 20, and at least one pharmaceutically acceptable excipient.
- 32. (new) The pharmaceutical composition of claim 31, further comprising a nucleic acid that comprises a sequence that encodes a peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.

- 33. (new) The pharmaceutical composition of claim 32, comprising:
- (a) the nucleic acid that encodes the peptide consisting of the amino acid sequence of SEQ ID NO: 2;
- (b) the nucleic acid that encodes the peptide consisting of the amino acid sequence of SEQ ID NO: 3 ; and
- (c) the nucleic acid that encodes the peptide consisting of the amino acid sequence of SEQ ID NO: 4.
- 34. (new) The pharmaceutical composition of claim 32, wherein said nucleic acids (a) to (c) are carried in a single vector.
- 35. (new) A method for preparing a medicament for the treatment of a pathology associated with an angiogenesis, comprising adding the isolated peptide of claim 20 to a pharmaceutically acceptable vehicle.
- 36. (new) The method of claim 35, wherein said isolated peptide is combined with a second peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO: 4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.
- 37. (new) The method of claim 35, wherein the amino sequence of said second peptide consists of SEQ ID NO: 4.

Docket No. 0512-1277 Appln. No. 10/533,443

- 38. (new) A method for preparing a medicament for the treatment of a pathology associated with an angiogenesis, comprising adding the nucleic acid of claim 23 to a pharmaceutically acceptable vehicle.
- 39. (new) The method of claim 38, wherein the nucleic acid comprises a sequence that encodes a peptide consisting of an amino acid sequence at least 90% identical to SEQ ID NO:4, and exhibiting an angiogenesis inhibiting activity and a capacity for binding to the ALK receptor.
- 40. (new) The method of claim 35, wherein the pathology is a tumour, an ocular lesion, rheumatoid polyarthritis or a skin disease.